Flecainide

Antiarrhythmic — CARDIOVASCULAR SYSTEM

Key facts

Flecainide is an ofp drug in the Antiarrhythmic class catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 8 molecular targets, including KCNH2, SCN5A and KCNA7. Recorded indications include Atrial fibrillation, Life-Threatening Ventricular Tachycardia, Paroxysmal atrial fibrillation and Paroxysmal atrial flutter.

• Approval status: ofp (first approved 1985 by the FDA).
• Drug class: Antiarrhythmic.
• Molecular targets: KCNH2, SCN5A, KCNA7 and Kcnd2 (8 listed in DrugCentral).
• Indications: Atrial fibrillation, Life-Threatening Ventricular Tachycardia, Paroxysmal atrial fibrillation, Paroxysmal atrial flutter and Prevention of Paroxysmal Supraventricular Tachycardia.
• ATC code: C01BC04 (Antiarrhythmics, class Ic).
• Molecular formula: C17H20F6N2O3; molecular weight 414.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Atrial fibrillation
• Life-Threatening Ventricular Tachycardia
• Paroxysmal atrial fibrillation
• Paroxysmal atrial flutter
• Prevention of Paroxysmal Supraventricular Tachycardia

Off-label uses (1)

• Cardioversion of Atrial Fibrillation

Contraindications (12)

• Cardiogenic shock
• Chronic heart failure
• Complete atrioventricular block
• Disease of liver
• Hyperkalemia
• Hypokalemia
• Kidney disease
• Myocardial infarction
• Right Bundle Branch Block with Left Hemiblock
• Second degree atrioventricular block
• Sick sinus syndrome
• Smokes tobacco daily

Mechanism & targets

• Established pharmacologic class: Antiarrhythmic

Molecular targets (8)

Target	Gene	Action	Activity
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.41
Sodium channel protein type 5 subunit alpha	SCN5A	blocker	IC50 5.19
Potassium voltage-gated channel subfamily A member 7	KCNA7	blocker	Kd 5.10
Potassium voltage-gated channel subfamily D member 2	Kcnd2	unknown	IC50 5.00
Sodium channel protein type 4 subunit alpha	SCN4A	unknown	Ki 4.75
Potassium voltage-gated channel subfamily C member 1	Kcnc1	blocker	IC50 4.00
Potassium voltage-gated channel subfamily A member 5	KCNA5	blocker	Kd 4.00
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	HCN4	unknown	IC50 2.77

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-10-31	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C01BC04	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ic

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Electrocardiogram QRS complex prolonged	1429.6
Bradycardia	612.0
Toxicity to various agents	610.9
Electrocardiogram QT prolonged	522.5
Ventricular tachycardia	508.6
Atrial fibrillation	452.5
Drug interaction	338.7
Atrial flutter	332.6
Cardiac arrest	301.4
Atrioventricular block first degree	281.2
Bundle branch block right	261.9
Brugada syndrome	249.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Flecainide is on its molecule page.

• Molecular formula: C₁₇H₂₀F₆N₂O₃
• Molecular weight: 414.35 g/mol
• CAS number: —
• InChIKey: DJBNUMBKLMJRSA-UHFFFAOYSA-N
• PubChem CID: 3356

FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flecainide used for?

DrugCentral lists the following indications for Flecainide: Atrial fibrillation, Life-Threatening Ventricular Tachycardia, Paroxysmal atrial fibrillation, Paroxysmal atrial flutter and Prevention of Paroxysmal Supraventricular Tachycardia.

How does Flecainide work?

Its molecular targets in DrugCentral include KCNH2, SCN5A (blocker), KCNA7 (blocker) and Kcnd2.

When was Flecainide first approved?

Flecainide was first approved by the FDA in 1985.

What drug class does Flecainide belong to?

Flecainide is in the Antiarrhythmic class.

What is the chemical formula of Flecainide?

Flecainide has the molecular formula C17H20F6N2O3 and a molecular weight of 414.35 g/mol.

Sources

• DrugCentral drug card 1176 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200822 — compound record and bioactivity
• PubChem CID 3356 — chemical identifiers
• DrugBank DB01195 — drug record
• FDA UNII K94FTS1806 — substance identity
• DailyMed: FDA labels for Flecainide — current prescribing information (label search)
• UniProt Q12809 (KCNH2) — target protein
• UniProt Q14524 (SCN5A) — target protein
• UniProt Q96RP8 (KCNA7) — target protein
• UniProt P35499 (SCN4A) — target protein
• UniProt P22460 (KCNA5) — target protein
• UniProt Q9Y3Q4 (HCN4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.